#USA #New York #Levi & Korsinsky #Sarepta Therapeutics #SRPT

Investors in Sarepta Therapeutics, Inc. Should Act Now

Investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) are notified that there is an ongoing class action lawsuit that may have significant implications for shareholders. The legal firm Levi & Korsinsky, LLP is representing individuals who experienced financial losses due to alleged securities fraud by the company.

Overview of the Situation

From June 22, 2023, until June 24, 2025, Sarepta has faced scrutiny over claims that may have misinformed investors regarding the safety of its gene therapy product, ELEVIDYS, which targets Duchenne muscular dystrophy. Levi & Korsinsky emphasizes the importance of contacting them before the deadline on August 25, 2025, if you believe you were impacted during this time.

Allegations Against Sarepta

The lawsuit asserts that Sarepta, along with certain executive officers, failed to disclose crucial information regarding ELEVIDYS. Some of the critical points of contention include:
1. Concerns about significant safety risks associated with the drug that were not appropriately communicated to investors.
2. Inadequate trial protocols that overlooked severe side effects of the treatment.
3. The eventual need to halt patient recruitment and dosing due to adverse events.
4. Regulatory scrutiny that surfaced afterward, further jeopardizing the therapy's approval and market expansion.

These factors have led to considerable doubts regarding the validity of Sarepta's optimistic statements about the drug's performance and safety.

Your Rights as an Investor

If you have sustained losses in Sarepta during the aforementioned period, you have the opportunity to request to be appointed as a lead plaintiff in this class action. This request must be submitted no later than August 25, 2025. It is critical to understand that participating as a class member does not necessitate serving as a lead plaintiff; you may still be eligible for compensation without incurring any out-of-pocket costs or fees.

Why Levi & Korsinsky?

Levi & Korsinsky has built a reputation over the past two decades for effectively securing financial redress for aggrieved shareholders. Their team specializes in complex securities litigation, boasting a track record of securing hundreds of millions of dollars for clients. They have been consistently ranked among the top securities litigation firms in the United States. With over 70 dedicated professionals, Levi & Korsinsky is positioned to provide comprehensive support and guidance for affected investors.

How to Proceed

For investors wishing to engage with Levi & Korsinsky regarding this matter, several options are available to initiate contact. You can reach out to Joseph E. Levi, Esq. at (212) 363-7500, or send an email to the provided contact address for more information.

Conclusion

Investors play a critical role in the financial health of companies like Sarepta Therapeutics. As a shareholder, staying informed about potential legal actions can significantly affect your investment strategy. Don’t miss the opportunity to discuss your rights before the deadline—act promptly to understand your options and take the next steps. Levi & Korsinsky is available to assist you through this process.